

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

SECTION 1: IDENTIFICATION

Product name : Levamisole / Oxfendazole Formulation

Other means of identification : Scanda (A007130)

Manufacturer or supplier's details

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Reproductive toxicity : Category 1B

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 4.0 | 14.04.2025 | 10808163-00007 | 06.07.2024 |
| | | | Date of first issue: 05.07.2022 |

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|------------------------------|------------|-----------------------|
| levamisole hydrochloride | 16595-80-5 | ≥ 3 - < 10 |
| oxfendazole | 53716-50-0 | ≥ 0.3 - < 10 |
| Polyethylene glycol stearate | 9004-99-3 | < 10 |
| Citric acid | 77-92-9 | < 10 |

SECTION 4. FIRST AID MEASURES

- | | |
|---|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air. Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : May damage fertility. May damage the unborn child. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

SECTION 5. FIREFIGHTING MEASURES

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
- Hazchem Code : •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|------------------------------|---------------------------|----------------------------------|--|----------|
| levamisole hydrochloride | 16595-80-5 | TWA | 20 µg/m ³ (OEB 3) | Internal |
| | Further information: Skin | | | |
| | | Wipe limit | 200 µg/100 cm ² | Internal |
| oxfendazole | 53716-50-0 | TWA | 40 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 400 µg/100 cm ² | Internal |
| Polyethylene glycol stearate | 9004-99-3 | TWA | 10 mg/m ³ | AU OEL |
| | | TWA (Inhalable particu- | 10 mg/m ³ | ACGIH |

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808163-00007 Date of last issue: 06.07.2024
 Date of first issue: 05.07.2022

| | | | | |
|--|--|-------------------------------------|---------------------|-------|
| | | late matter) | | |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
 Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

| | | |
|--|---|--|
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity Viscosity, kinematic | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle characteristics Particle size | : | Not applicable |

SECTION 10. STABILITY AND REACTIVITY

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | Can react with strong oxidizing agents. |
| Conditions to avoid | : | None known. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION

| | | |
|-----------------|---|--|
| Exposure routes | : | Inhalation Skin contact Ingestion Eye contact |
|-----------------|---|--|

Acute toxicity

Not classified based on available information.

Product:

| | | |
|---------------------|---|--|
| Acute oral toxicity | : | Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method |
|---------------------|---|--|

Components:**levamisole hydrochloride:**

| | | |
|---------------------------|---|--|
| Acute oral toxicity | : | LD50 (Rat): 180 mg/kg LD50 (Mouse): 223 mg/kg LD50 (Rabbit): 458 mg/kg |
| Acute inhalation toxicity | : | Remarks: No data available |
| Acute dermal toxicity | : | Remarks: No data available |

oxfendazole:

| | | |
|---------------------|---|---|
| Acute oral toxicity | : | LD50 (Rat): > 6,000 mg/kg LD50 (Dog): 1,600 mg/kg LD50 (sheep): 250 mg/kg |
|---------------------|---|---|

Polyethylene glycol stearate:

| | | |
|---------------------|---|---------------------------|
| Acute oral toxicity | : | LD50 (Rat): > 5,000 mg/kg |
|---------------------|---|---------------------------|

Citric acid:

| | | |
|-----------------------|---|---------------------------|
| Acute oral toxicity | : | LD50 (Mouse): 5,400 mg/kg |
| Acute dermal toxicity | : | LD50 (Rat): > 2,000 mg/kg |

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**levamisole hydrochloride:**

Remarks : No data available

oxfendazole:

| | |
|---------|----------------------|
| Species | : Rabbit |
| Result | : No skin irritation |

Polyethylene glycol stearate:

| | |
|---------|----------------------|
| Species | : Rabbit |
| Method | : Draize Test |
| Result | : No skin irritation |

Citric acid:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : No skin irritation |

Serious eye damage/eye irritation

Not classified based on available information.

Components:**levamisole hydrochloride:**

Remarks : No data available

oxfendazole:

| | |
|---------|---------------------|
| Species | : Rabbit |
| Result | : No eye irritation |

Polyethylene glycol stearate:

| | |
|---------|---------------------|
| Species | : Rabbit |
| Result | : No eye irritation |
| Method | : Draize Test |

Citric acid:

| | |
|---------|--|
| Species | : Rabbit |
| Result | : Irritation to eyes, reversing within 21 days |
| Method | : OECD Test Guideline 405 |

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**levamisole hydrochloride:**

|| Remarks : No data available

Polyethylene glycol stearate:

|| Test Type : Open epicutaneous test
|| Exposure routes : Skin contact
|| Species : Guinea pig
|| Result : negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**levamisole hydrochloride:**

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
|| Result: negative
|| Test Type: Chromosome aberration test in vitro
|| Result: negative

oxfendazole:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
|| Result: negative
|| Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow
|| cytogenetic test, chromosomal analysis)
|| Species: Mouse
|| Application Route: Oral
|| Result: positive

Polyethylene glycol stearate:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
|| Result: negative

Citric acid:

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) |
| | | Result: negative |
| | | Test Type: in vitro micronucleus test |
| | | Result: positive |
| | | Test Type: Bacterial reverse mutation assay (AMES) |
| | | Result: negative |
| Genotoxicity in vivo | : | Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) |
| | | Species: Rat |
| | | Application Route: Ingestion |
| | | Result: negative |

Carcinogenicity

Not classified based on available information.

Components:**levamisole hydrochloride:**

| | | |
|-------------------|---|--|
| Species | : | Mouse |
| Application Route | : | Oral |
| Exposure time | : | 2 Years |
| NOAEL | : | 80 mg/kg body weight |
| Remarks | : | No significant adverse effects were reported |

| | | |
|-------------------|---|--|
| Species | : | Rat |
| Application Route | : | Oral |
| Exposure time | : | 2 Years |
| NOAEL | : | 40 mg/kg body weight |
| Remarks | : | No significant adverse effects were reported |

oxfendazole:

| | | |
|-------------------|---|--------------------|
| Species | : | Rat |
| Application Route | : | Oral |
| Exposure time | : | 1 Years |
| Symptoms | : | No adverse effects |
| Target Organs | : | Liver |

| | | |
|-------------------|---|--------------------|
| Species | : | Rat |
| Application Route | : | Oral |
| Exposure time | : | 2 Years |
| Symptoms | : | No adverse effects |
| Target Organs | : | Liver |

Reproductive toxicity

May damage fertility. May damage the unborn child.

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Components:**levamisole hydrochloride:**

- | | | |
|------------------------------------|---|---|
| Effects on fertility | : | Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

oxfendazole:

- | | | |
|-------------------------------|---|---|
| Effects on fertility | : | Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects |

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

| | |
|------------------------------------|---|
| | Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-foetal toxicity |
| | Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities |
| | Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight |
| Reproductive toxicity - Assessment | : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments. |

Citric acid:

| | |
|-------------------------------|---|
| Effects on foetal development | : Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative |
|-------------------------------|---|

STOT - single exposure

Not classified based on available information.

Components:**Citric acid:**

| | |
|------------|-------------------------------------|
| Assessment | : May cause respiratory irritation. |
|------------|-------------------------------------|

STOT - repeated exposure

Not classified based on available information.

Components:**levamisole hydrochloride:**

| | |
|---------------|--|
| Target Organs | : Blood, Testis |
| Assessment | : May cause damage to organs through prolonged or repeated exposure. |

oxfendazole:

| | |
|-----------------|--|
| Exposure routes | : Oral |
| Target Organs | : Liver, Testis |
| Assessment | : May cause damage to organs through prolonged or repeated exposure. |

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Repeated dose toxicity**Components:****levamisole hydrochloride:**

| | |
|-------------------|-------------|
| Species | : Rat |
| NOAEL | : 2.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 18 Months |
| Target Organs | : Testis |

| | |
|-------------------|-------------|
| Species | : Dog |
| LOAEL | : 20 mg/kg |
| Application Route | : Oral |
| Exposure time | : 18 Months |
| Target Organs | : Blood |

| | |
|-------------------|------------|
| Species | : Dog |
| LOAEL | : 40 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |

oxfendazole:

| | |
|-------------------|------------------------|
| Species | : Rat |
| NOAEL | : 11 mg/kg |
| Application Route | : Oral |
| Exposure time | : 2 Weeks |
| Target Organs | : Blood, Liver, Testis |

| | |
|-------------------|-----------------|
| Species | : Rat |
| NOAEL | : 3.8 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |
| Target Organs | : Liver, Testis |

| | |
|-------------------|-------------|
| Species | : Mouse |
| NOAEL | : 750 mg/kg |
| Application Route | : Oral |
| Exposure time | : 1 Months |
| Target Organs | : Liver |

| | |
|-------------------|--------------|
| Species | : Mouse |
| NOAEL | : 37.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |
| Target Organs | : Liver |

| | |
|-------------------|--|
| Species | : Dog |
| NOAEL | : 6 mg/kg |
| Application Route | : Oral |
| Exposure time | : 1 Months |
| Remarks | : No significant adverse effects were reported |

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

| | |
|-------------------|-----------------------------|
| Species | : Dog |
| NOAEL | : 11 mg/kg |
| Application Route | : Oral |
| Exposure time | : 2 Weeks |
| Target Organs | : Lymph nodes, thymus gland |

| | |
|-------------------|--------------|
| Species | : Dog |
| NOAEL | : 13.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 12 Months |
| Target Organs | : Liver |

Citric acid:

| | |
|-------------------|---------------|
| Species | : Rat |
| NOAEL | : 4,000 mg/kg |
| LOAEL | : 8,000 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 10 Days |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****levamisole hydrochloride:**

| | |
|-----------|--|
| Ingestion | : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension |
|-----------|--|

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****levamisole hydrochloride:**

| | |
|---|---|
| Toxicity to fish | : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |

oxfendazole:

| | |
|------------------|--|
| Toxicity to fish | : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l Exposure time: 96 h LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l |
|------------------|--|

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 4.0 | 14.04.2025 | 10808163-00007 | 06.07.2024 |
| | | | Date of first issue: 05.07.2022 |

| | |
|--|--|
| | Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 0.059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC (Daphnia magna (Water flea)): 0.023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 |

Polyethylene glycol stearate:

| | |
|----------------------------|--|
| Toxicity to fish | : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l Exposure time: 96 h Method: DIN 38412 |
| Toxicity to microorganisms | : EC10 (Bacteria): > 10,000 mg/l Exposure time: 16 h |

Citric acid:

| | |
|---|--|
| Toxicity to fish | : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h |

Persistence and degradability**Components:****oxfendazole:**

| | |
|--------------------|---------------------------|
| Stability in water | : Hydrolysis: < 5 % (4 d) |
|--------------------|---------------------------|

Polyethylene glycol stearate:

| | |
|------------------|---|
| Biodegradability | : Result: Readily biodegradable. Biodegradation: > 70 % Exposure time: 10 d Method: OECD Test Guideline 302B |
|------------------|---|

Citric acid:

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential**Components:****oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

Mobility in soil**Components:****oxfendazole:**

Distribution among environmental compartments : log Koc: 3.2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxfendazole)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(oxfendazole)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(oxfendazole)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(oxfendazole)

Class : 9

Packing group : III

Labels : 9

Hazchem Code : •3Z

Environmentally hazardous : yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument : Schedule 5 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

| | |
|-------|------------------|
| AICS | : not determined |
| DSL | : not determined |
| IECSC | : not determined |

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

| | |
|---|---|
| Revision Date | : 14.04.2025 |
| Sources of key data used to compile the Safety Data Sheet | : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/ |

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

| | |
|-------------|--------------|
| Date format | : dd.mm.yyyy |
|-------------|--------------|

Full text of other abbreviations

| | |
|--------------|--|
| ACGIH | : USA. ACGIH Threshold Limit Values (TLV) |
| AU OEL | : Australia. Workplace Exposure Standards for Airborne Contaminants. |
| ACGIH / TWA | : 8-hour, time-weighted average |
| AU OEL / TWA | : Exposure standard - time weighted average |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

Levamisole / Oxfendazole Formulation

| | | | |
|---------|----------------|----------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 4.0 | 14.04.2025 | 10808163-00007 | Date of first issue: 05.07.2022 |

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN